{"nctId":"NCT02073656","briefTitle":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection","startDateStruct":{"date":"2014-02"},"conditions":["Hepatitis C Virus","HIV"],"count":335,"armGroups":[{"label":"LDV/SOF 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"Retreatment Substudy","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HCV RNA ≥ 10,000 IU/mL at screening\n* HCV genotype 1 or 4\n* HIV-1 infection\n* Cirrhosis determination, a fibroscan or liver biopsy may be required\n* Screening laboratory values within defined thresholds\n* Use of protocol specified method(s) of contraception if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol\n* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC), or other malignancy (with the exception of certain resolved skin cancers)\n* Hepatitis B virus (HBV) infection\n* Pregnant or nursing female\n* Chronic use of systemically administered immunosuppressive agents","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, and 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.68","spread":"0.674"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.21","spread":"0.654"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":"0.743"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":"0.772"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.33","spread":"0.645"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Creatinine at the End of Treatment (Week 12) and at Posttreatment Weeks 12 and 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.134"}]}]}]},{"type":"SECONDARY","title":"For Participants in the Retreatment Substudy, Percentage of Participants With SVR at 4, 12, and 24 Weeks After Discontinuation of Therapy (SVR4, SVR12, and SVR24)","description":"SVR4, SVR12, and SVR 24 were defined as HCV RNA \\< LLOQ at 4, 12, and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]}]},{"type":"SECONDARY","title":"For Participants in the Retreatment Substudy, Percentage of Participants With HCV RNA < LLOQ at Retreatment Weeks 2, 4, 8, 12, 16, 20, and 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"For Participants in the Retreatment Substudy, Change From Baseline in HCV RNA at Retreatment Weeks 2, 4, and 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.01","spread":"0.775"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.04","spread":"0.802"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.04","spread":"0.802"}]}]}]},{"type":"SECONDARY","title":"For Participants in the Retreatment Substudy, Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":335},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Arthralgia"]}}}